1Division of Neurosurgery, Department of Surgery, and.
2Dalla Lana School of Public Health, University of Toronto, Ontario, Canada.
Neurosurg Focus. 2020 Jun;48(6):E4. doi: 10.3171/2020.3.FOCUS2044.
Cushing's disease (CD) patients experience a range of debilitating symptoms that impair quality of life (QOL) as assessed using generic measures. These generic measures are inadequate to capture the disease-specific burden of illness. The development of the CD-specific QOL-CD measure of QOL using items generated by CD patients and healthcare professionals will provide a holistic assessment of patient outcomes and efficacy of novel therapies.
A total of 96 CD patients participated. A list of 177 items (version 1.0) was generated by treated CD patients (n = 9), caregivers (n = 2), healthcare providers (n = 7), and results of a MEDLINE search. Item reduction was performed through content analysis and dual scaling. Patients' rating of importance was incorporated to reduce to a final version of 56 items (version 3.0). Evidence for test-retest reliability was sought through administering the QOL-CD 1 week apart and Cronbach's α of each subscale. Construct validity was assessed through extreme group analysis and comparison with the normal Canadian population. Concurrent validity was sought through comparison with the SF-36, Functional Assessment of Cancer Therapy-Brain (FACT-Br), and Karnofsky Performance Status (KPS). Perioperative testing was conducted on CD patients (n = 25) against nonfunctioning pituitary adenoma controls (n = 25) through pre- and postoperative testing.
A total of 96 CD patients (86 females and 10 males; mean age 45.23 ± 14.16 years) participated. The QOL-CD was feasible (mean completion time 15 minutes, with 70% believing accurate capture of QOL), reliable (CD 1 week apart: r = 0.86; control 1 week apart: r = 0.83; Cronbach's α: general health = 0.73, emotional health = 0.85, physical health = 0.78, mental status = 0.82, social well-being = 0.63, medical treatment = 0.54), and valid (extreme group testing p < 0.001; SF-36 and QOL-CD general health: r = 0.56, social well-being: r = 0.21, emotional health: r = 0.61, total score: r = 0.58; FACT-Br and QOL-CD physical health: r = 0.47, social well-being: r = 0.21, emotional health: r = 0.34, total score: r = 0.68; KPS and QOL-CD general health: r = 0.32, total score: r = 0.14). Perioperative testing of CD patients (n = 25) demonstrated improvement in all subscales postoperatively, with a significant difference in emotional health (p < 0.001) and physical health (p < 0.001).
The QOL-CD questionnaire has been developed for patients with CD and has demonstrated evidence for validity and reliability.
库欣病(CD)患者经历一系列使人虚弱的症状,这些症状会降低生活质量(QOL),而使用通用措施进行评估。这些通用措施不足以捕捉疾病特有的疾病负担。使用 CD 患者和医疗保健专业人员生成的项目开发 CD 特异性 QOL-CD 生活质量量表,将为患者结局和新疗法的疗效提供全面评估。
共有 96 名 CD 患者参与。通过治疗的 CD 患者(n=9)、护理人员(n=2)、医疗保健提供者(n=7)以及 MEDLINE 搜索结果生成了 177 项清单(版本 1.0)。通过内容分析和双重标度进行项目缩减。将患者的重要性评分纳入其中,以将其减少至最终的 56 项(版本 3.0)。通过在一周后分开管理 QOL-CD 并获得每个子量表的 Cronbach's α,寻求测试-重测信度的证据。通过极端组分析和与正常加拿大人群进行比较来评估构念效度。通过与 SF-36、癌症治疗功能评估-脑(FACT-Br)和卡氏行为状态量表(KPS)进行比较来寻求同时效性。对接受手术的 CD 患者(n=25)与无功能垂体腺瘤对照(n=25)进行了围手术期测试。
共有 96 名 CD 患者(86 名女性和 10 名男性;平均年龄 45.23±14.16 岁)参与了研究。QOL-CD 是可行的(平均完成时间为 15 分钟,70%的患者认为准确地捕捉到了 QOL),可靠(CD 一周后分开:r=0.86;对照一周后分开:r=0.83;Cronbach's α:一般健康=0.73,情绪健康=0.85,身体健康=0.78,精神状态=0.82,社会福利=0.63,医疗=0.54),并且有效(极端组测试 p<0.001;SF-36 和 QOL-CD 一般健康:r=0.56,社会福利:r=0.21,情绪健康:r=0.61,总分:r=0.58;FACT-Br 和 QOL-CD 身体健康:r=0.47,社会福利:r=0.21,情绪健康:r=0.34,总分:r=0.68;KPS 和 QOL-CD 一般健康:r=0.32,总分:r=0.14)。接受手术的 CD 患者(n=25)的围手术期测试显示术后所有子量表均有改善,情绪健康(p<0.001)和身体健康(p<0.001)有显著差异。
已为 CD 患者开发了 QOL-CD 问卷,并已证明其具有有效性和可靠性。